Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.
Amgen is paying up to resolve claims that it broke the rules while marketing anemia drug Aranesp and anti-inflammatory blockbuster Enbrel. The company has settled with 48 states for $71 million, marking the latest state-level crackdown on alleged marketing violations in the pharma industry.
Just months after inking a $246 million development deal with Baxter for a biosimilar of Enbrel, Redwood City, CA-based Coherus has rounded up a whopping $55 million C round, including cash from KKR.
The company will reformulate drugs already approved for humans and market them for pets, and expects FDA approval for three drugs for dogs by the end of the year.
It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.
Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...
A 9-year run for VLST has ended. The Seattle biotech outfit has peddled assets to undisclosed buyers for undisclosed terms and shut its doors for good, Xconomy 's Luke Timmerman reported.
Novartis says that one of its top Phase III drug prospects beat out Enbrel in a head-to-head showdown on psoriasis. Investigators say that the anti-IL17A secukinumab (AIN457) nabbed all the primary and secondary endpoints in the study.
Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.
Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz--about $3 billion worth. But those expectations were struck a serious blow when European Medicines Agency regulators Thursday turned it down for approval.